Kornimate/medical-research-clean huggingface dataset:
hev in patients with acute non-a, non-b, non-c hepatitis in al-rajhy university hospital for liver

Conditions: Hepatitis E

Summary: hepatitis e is the fifth known human viral hepatitis and is probably the most common cause of acute viral hepatitis in the world. the incidence of acute hepatitis e is estimated at 3 million human cases per year worldwide, with around 70,000 deaths. most cases occur in endemic countries, but the number of cases in low-endemic areas has increased. hev seroprevalence is high in developing countries, such as india and southeast asia, ranging from 27-80%. acute disease mortality is 1-4%, with risk being higher in pregnant women and immunodeficient patients. the four more prevalent genotypes are allocated into two groups. epidemic hepatitis e includes genotypes 1 and 2, which are considered human viruses and have caused the epidemics of hepatitis. these forms are transmitted mainly by contaminated water and the fecal-oral route. endemic hepatitis e includes genotypes 3 and 4, which are considered swine viruses (common in domestic and wild pigs), capable of infecting humans as an accidental host and therefore considered zoonotics. the course and clinical presentation of hepatitis e is highly variable. the detailed mechanisms that lead to the different clinical outcomes in hepatitis e are only partially understood. it is known that both viral factors (genotype and dose of inoculum) and host factors (presence of previous liver disease, pregnancy and distinct genetic polymorphisms) determine the course of infection. in most cases, hepatitis e causes self-limited illness, lasting from a few days to weeks, with an average of 4-6 weeks. however, in developed countries it can cause chronic disease with rapid progression to cirrhosis, especially in patients who are transplanted, have hematological malignancies requiring chemotherapy, or have infection with hiv. hepatitis e is an underdiagnosed disease, partly due to the use of serological tests with low sensitivity. diagnosis can be made indirectly by detecting antibodies against hev in the serum, or directly by detecting the genome of the virus in blood or other body fluids. the tests for anti-hepatitis e antibody screening are commercially available, but none of them has been approved by the food and drug administration (fda). unfortunately, the sensitivity and specificity of these tests vary greatly and this could explain the discrepancies in rates of anti-hepatitis e antibodies published for the various populations studied. the tests for viral rna in serum and feces are confirmatory, but still experimental.


Eligibility criteria:
inclusion criteria: * • patients have clinical diagnosis of acute viral hepatitis as (recent onset of nausea, fever, fatigue, abdominal pain , hepatomegaly and abnormal transaminases (at least 2 fold higher than the upper normal level)) * post-transplant acute hepatitis exclusion criteria: * hepatitis a, b and c patients * autoimmune hepatitis * alcoholism * treatment with hepatotoxic drugs * biliary disease * infection with cmv or ebv * taken ribavirin therapy
effect of continuous thoracic epidural analgesia on gut motility following emergency laparotomy

Conditions: Analgesia, Epidural

Summary: continuous thoracic epidural analgesia plays a very vital role in patients undergoing exploratory laparotomy. it not only supports a stable perioperative hemodynamics but also helps in early return of bowel activity.

intestinal perforation is one of the commonest surgical emergency that the investigators encounter in emergency. perioperative management of most of such patients is a challenging task for the anesthesiologist, as patients are often hemodynamically unstable at the time of their presentation to emergency. usual plan of anesthesia for these patients is general anesthesia with or without an epidural block. in routine practice the investigators often place an epidural catheter, primarily for postoperative analgesia, unless there is some contraindication to epidural analgesia. most often lower thoracic epidural is preferred because of longer length of the laparotomy incision. thoracic epidural analgesia with local anesthetic (la) is not only effective in managing the post-operative pain; it is also helpful in supplementing intra-operative analgesia with reduced requirement of anesthetic, muscle relaxant and the analgesic (opioid) drugs. in addition, it has also been reported to be associated with early return of gut motility. it appears that absent / significantly reduced pain leads to lesser stress response, leading to less sympathetic activation and lesser catecholamine release. as catecholamines are inhibitory to gastrointestinal motility, earlier return of gastro intestinal (gi) motility can be achieved by reducing perioperative pain by continuous epidural analgesia. moreover, an effective epidural analgesia with la results in avoidance of opioid analgesics for optimal perioperative pain relief, which too may be helpful in achieving earlier return of gut motility. thus the investigators aimed at determining the effect of continuous thoracic epidural analgesia on return of gut motility in patients undergoing emergency exploratory laparotomy following intestinal perforation and compare it with those in whom epidural analgesia was not used.

Eligibility criteria:
inclusion criteria: * both sexes * age 20-60 years * intestinal perforation posted for emergency exploratory laparotomy exclusion criteria: * patient's refusal and uncooperativeness for epidural analgesia * hemodynamically unstable patients * patients with coagulation disorder * infection at the site of epidural insertion * spine deformity or spinal cord disease * raised intracranial pressure * history of drug abuse * other comorbid conditions like diabetes mellitus, hypertension, thyroid disease
oral carvedilol in escalating doses in the acute treatment of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: oral carvedilol administered in escalating doses in patients with atrial fibrillation among patients with af with fast ventricular rate.

patients with af with fvr of any etiology were evaluated and given escalating doses of oral carvedilol in doses - 3.125mg od, then 3.125 bid, then 6.25mg bid, then 12.5mg bid. the ecg was recorded regularly and analysed for rate reduction or control.

Eligibility criteria:
inclusion criteria: * af with fast ventricular rate exclusion criteria: -

Keywords: atrial fibrillation rate reduction
public title：a study on the registration of the use of feilike heji in adults

Conditions: Bronchial Asthma

Summary: feilike heji is produced by guizhou jianxing pharmaceutical co. ltd. for the treatment of phlegm heat caused by lung cough phlegm yellow, bronchial asthma, bronchitis, see the syndrome of proprietary chinese medicine (approval number: z20025136) approved by the state and the drug from radix scutellariae, radix peucedani, radix stemonae, red gentian root of deal, phoenix tree, spreading hedyotis herb, red tube 7 flavour, with qingrejiedu, antitussive expectorant effect. in order to fully understand the safety of feilike heji in clinical practice and fulfill the responsibility of production enterprises for patients, the production enterprises initiated this study to further evaluate the safety and understanding of the function characteristics of feilike heji in a wide range of people, so as to guide the clinical rational drug use.


Eligibility criteria:
inclusion criteria: * all adult patients (age ≥18 years old) who use feilike heji at the specified monitoring time and in the monitoring center (department) ; * must voluntarily participate in this study; * must meet ethical requirements. exclusion criteria: * no
hyperbaric oxygen therapy as a neuroprotective modality in pediatric acquired brain injury with motor disability

Conditions: Hyperbaric Oxygen Therapy; Neuroprotective; Pediatric; Acquired Brain Injury; Motor Disability

Summary: this study aimed to assess the efficacy of hyperbaric oxygen therapy as a neuroprotective intervention in children with acquired brain injury.

pediatric acquired brain injury (abi) represents a significant challenge in modern medicine, necessitating innovative therapeutic approaches to enhance recovery and minimize long-term neurological deficits. hyperbaric oxygen therapy (hbot), which delivers oxygen at pressures exceeding atmospheric levels, has emerged as a promising neuroprotective intervention for various forms of pediatric brain injury, including traumatic brain injury (tbi), anoxic-ischaemic encephalopathy (aie), and stroke.

Eligibility criteria:
inclusion criteria: * age 4-12 years. * diagnosed with pediatric acquired brain injury confirmed by neurological examination and magnetic resonance imaging. * presence of neurological sequelae (e.g., cardiac arrest, intracranial hemorrhage, central nervous system infection, stroke, tumor, hypoxia). exclusion criteria: * positive family history of degenerative brain insults. * behavioral problems. * contraindications to hyperbaric oxygen therapy : * active epilepsy. * respiratory insufficiency. * uncontrolled heart failure. * eustachian tube dysfunction. * tympanic membrane rupture. * mechanical ventilation dependency.
olanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia

Conditions: Schizophrenia

Summary: to compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia * must be an outpatient (not requiring hospitalization) now and for at least the past 8 weeks. * disease symptoms must meet a certain range as assessed by the clinician. * patient has experienced at least two episodes of clinical worsening of their condition. this could mean admission to a hospital or an emergency room visit. this could mean that a new medication was added, medication dose was increased, or medication was switched in order to better control symptoms of the condition. * the patient must have an unsatisfactory response to their current medication or be experiencing negative effects of their current medication or not always take their current medication so that a change in current medication is desired. exclusion criteria: * patients who are actively suicidal. * patients who are pregnant or nursing. * patients who have stopped past treatment with olanzapine because of adverse events, are treatment resistant or allergic to olanzapine, or have a condition which would prevent use of a long acting form of olanzapine. * patients with uncorrected narrow-angle glaucoma, seizures, uncontrolled diabetes, certain diseases of the liver, uncontrolled thyroid condition or other serious or unstable illness. * patients with parkinson's disease, psychosis related to dementia or other related disorders.
investigation of a customized femoral resurfacing implant

Conditions: Articular Cartilage Disorder

Summary: the purpose is to assess the safety profile and performance of a femoral resurfacing implant for localized chondral lesions.

the implant's safety profile will be assessed by incidence of any subject having any of the seven identified implant-related clinical undesirable side effects. this will be analyzed with a one-side exact binomial test on significance level 0.05, at 24 months post-operatively.

Eligibility criteria:
inclusion criteria: 1. male or female 2. age 30 ≤ 65 years 3. chondral defects of the femoral cartilage icrs grade 3 (severely abnormal cartilage defects \> 50% of the cartilage depth) or grade 4 (severely abnormal, through the cartilage depth) on medial or lateral femoral condyles 4. cartilage lesion area \< 3.2 cm2 (diameter \< 2 cm) 5. failed earlier conservative or surgical interventions such as lavage, abrasions, drilling or microfracture 6. vas-pain symptom \>40 for more than 6 months 7. the arthroscopic finding corresponds to the expected; size of cartilage lesion is correct and no other significant pathology (see cip, "intra-operative check-list", appendix i) 8. capable of completing self-administered questionnaires 9. willing to comply with the follow-up requirements of the study 10. signed informed consent exclusion criteria: 1. bmi ≥ 35 kg/m2 (severe obesity) 2. instability or deficiency of soft tissues, vascular or muscular insufficiency 3. metabolic disorders which may impair bone formation 4. diabetes mellitus 5. smokers 6. diagnosis of a concomitant knee injury which the investigator appreciates may interfere with study participation (i.e. may confound efficacy assessment or healing at the involved knee joint level) 7. irresolvable joint pain or loss-of-function with an undeterminable cause 8. diagnosis of a concomitant meniscal injury in involved knee that requires surgical intervention 9. loss of joint space on standing radiographs (≥ 1 on ahlbäck-scale (0-5)) 10. avascular necrosis 11. infections, systemic or local 12. known metal allergies 13. history of inflammatory arthritis 14. pregnancy 15. pacemaker implant 16. history of drug or substance abuse 17. systemic administration within 30 days prior to the study of any type of corticosteroid, antineoplastics, immune stimulating or immunosuppressive agents 18. participation in another clinical trial using an investigational new drug or device within 30 days of entrance into this study. 19. condition that may have an impact on the outcome of the investigation as judged by the investigator.
registry of febrile neutropenia and invasive fungal infections

Conditions: Hematological Disease; Febrile Neutropenia; Fungal Infections

Summary: objectives： 1. to assess the percentage of febrile neutropenia and suspected fungal-related febrile episodes in patients receiving chemotherapy 2. to explore the percentage/distribution of infectious origins of febrile neutropenia 3. to explore the percentage/distribution of infectious pathogens of febrile neutropenia 4. to explore clinical outcomes of different infectious origins/pathogens in febrile neutropenia episodes 5. to have a clear view of therapeutic actions in the management of hematological patients with febrile neutropenia and suspected fungal-related febrile episodes

objectives： 1. to assess the percentage of febrile neutropenia and suspected fungal-related febrile episodes in patients receiving chemotherapy 2. to explore the percentage/distribution of infectious origins of febrile neutropenia 3. to explore the percentage/distribution of infectious pathogens of febrile neutropenia 4. to explore clinical outcomes of different infectious origins/pathogens in febrile neutropenia episodes 5. to have a clear view of therapeutic actions in the management of hematological patients with febrile neutropenia and suspected fungal-related febrile episodes study design： * this is a single institute, prospective, non-interventional registry for monitoring events of febrile neutropenia in hematological patients * patients with newly diagnosed malignant hematological diseases will be enrolled into this registry study procedures： data collection will include patients' basic information, underlying disease, baseline blood chemistry and blood cell counts, antifungal prophylaxis, c/t regimens, neutrophils and other blood cells, fever diagnosis and infectious sites work-up, clinical response, microbiology (including bacteria and fungus culture), renal and liver function, clinical diagnosis, work-up and intensive procedures and results, antifungal and antibacterial agents (including dosage, duration, and route), other drugs used (including antivirals, antineoplastics, corticosteroids, immunomodulators), clinical significant changes sample size calculation and statistical analysis： approximately 100 febrile neutropenia episodes in 500 chemotherapy cycles will be collected. this is an observational and exploratory study without hypothesis tests. study subjects will be collected and monitored under normal clinical practice, and the sample size will be limited due to the hospital scale and disease characteristic (the sample size calculation is inapplicable here). all evaluations will be shown by exploratory and descriptive data analysis. the number of cases for each investigative definition, the corresponding percentage and the 95% confidence interval will be described.

Eligibility criteria:
inclusion criteria: * patients with new diagnosed hematological diseases (acute and chronic myeloid and lymphoid leukemia, multiple myeloma, non-hodgkin's and hodgkin's lymphoma, myelodysplastic syndromes) * patients who are receiving chemotherapy and have ongoing febrile episodes exclusion criteria: * none
comparing the efficacy of an online gambling intervention to a no intervention control condition

Conditions: Gambling Problem

Summary: online interventions for gambling problems hold a strong potential to help people with gambling concerns. however, there are no trials, to-date, that have been able to demonstrate the effectiveness of such an intervention. the current trial will compare participants provided access to an online gambling intervention to those assigned by chance to a no intervention condition in order to test the efficacy of one such internet intervention for gambling. participants will be recruited through amazon's mturk crowdsourcing platform. potential participants identified as problem gamblers who are interested in quitting or reducing their gambling in the next 6 months, or often think about it, based on an initial survey will be invited to complete additional surveys at 6 weeks and 6 months. those who then agree to be followed up will be randomized to access an online intervention for gambling or a no-intervention website. these participants will then be contacted again at 6 weeks and 6 months to ask about their gambling, and their impressions of the online intervention. the primary hypothesis to be tested is that participants receiving access to the online gambling intervention will report a greater reduction in number of days gambling and in nods scores at 6-month follow-up than participants in the no intervention control condition.


Eligibility criteria:
inclusion criteria: * 18 years of age or over * a score of 5 or over on the problem gambling severity index (pgsi) * thinking about cutting down or quitting their gambling (in next 6 months, or state that they are thinking about it most or almost all of the time) * willingness to complete a 6-week and 6-month follow-up survey
comparison of kinesio taping and cervical thrust manipulation in neck pain

Conditions: Neck Pain

Summary: to compare the effects of kinesio taping, cervical thrust manipulation and conventional therapy on neck pain, functional status and range of motion

neck pain is most prevalent condition affecting globally, which also create threats to the individuals. mechanical neck pain affects mainly two third of population at some time in life possibly in middle age, some people may be acute mechanical neck pain while some leading to chronic stage. mechanical neck disorders usually associated with pain, decreased cervical mobility, spasm. often neck pain is mechanical in nature, according to literature mechanical neck pain is defined as, that pain originating from cervical spine which may be aggravated with cervical motion, prolonged posture, muscular stiffness. due to widespread occurrence of mechanical neck pain mainly in modern society, proper interventional strategies of this problem is needed to facilitate that problem. incidence of neck pain may range from 10.4-23.3%in one year, while according to previous literature prevalence of neck pain was 0.4 to 86.8%, with high proportion in office workers, computer users, and females especially 35 to 55 years. pain, stiffness, tenderness and restricted mobility is most common symptoms associated with neck pain, manual therapy techniques, exercises, mobilization, manipulations, kinesio taping are treatment strategies used for this problem may improve neck pain. the main purpose of my study is to improve neck pain, discomfort and functional status in patients with mechanical neck pain.

Eligibility criteria:
inclusion criteria: * subjects having mechanical neck pain. * participants having neck pain more than 1 month. exclusion criteria: * history of serious pathology (malignancy, inflammatory disorders). * cervical spinal surgery. * history of trauma or fracture. * vascular syndromes. * neurological and cardiac pathologies.

Keywords: mechanical neck pain kinesio taping cervical manipulation
experiences of participating in return to work group programmes

Conditions: Musculoskeletal Diseases or Conditions

Summary: to explore the experiences of individuals with musculoskeletal disorders (msds) who have participated in return-to-work group programmes (rtw-gps) and see how the programmes could strengthen their work ability.

for a representative sampling of experiences, participants who had participated in various groups over time in outpatient and inpatient groups in the rtw-gp were invited to enrol in the study. other inclusion criteria were age between 25 and 65 years, different musculoskeletal diagnosis and that they should come from the rural district/city of residence. the participants received requests by letter to participate in the focus group interview six months after the final group intervention, the same time as they were invited to a follow-up visit. only a few men had participated in the rtw-gps and none of them wanted to take part in the study. all participants were given written and oral information about the study, the use of recording and transcribing devices, and their right to withdraw from the study at any time. the interviews were carried out after the participants gave written, informed consent. three focus group interviews were conducted: one with six participants, and two with five. one participant who could not participate in the focus group interview participated at an individual interview with the same questions as in the focus groups. the individual interview was conducted first and served as a test for the questions in the interview guide. interventions the participants of this study had participated in one of three different rtw-gps. these programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. all the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important. motivation is instilled by helping participants recognise opportunities for change. participants set work-related goals and receive individual feedback from multidisciplinary personnel in addition to various group-based sessions with teaching, activities and exercises. the participants are referred to the programme by a rheumatologist or a member of the hospital's multidisciplinary team as soon as possible after starting sick-leave.

Eligibility criteria:
inclusion criteria: * participating rtw-gp * musculoskeletal diagnoses * from the rural district/city of residence * speaking norwegian

Keywords: qualitative study musculoskeletal disorders return to work programme